Martin Shaw, Business Development at AroCell, held a presentation on the Thymidine Kinase 1 immunoassay, highlighting its significance as a valuable translational biomarker from drug discovery through to clinical trials. You can see the presentation below.
Presentation of IDL Diagnostics Interim Report Q4 2025
CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q4’25 results – February 26, 2026 Q4 Interview: Redeye talks with CEO Anders Hultman
